PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10493966-7	1999	On day +10 (range +9 to +11) after the last dose of Topotecan, the median WBC count and the CD34+ cell peak were 8.2 x 10(3) microl (range 4.9-13.9) and 55 microl (range 28-75), respectively.	Topotecan	52-61	CD34 molecule	Homo sapiens	92-96	
9815746-14	1997	In 7 of 10 patients, there was an increase (16.6 +/- 2.9% to 25.0 +/- 3.5%; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas 1 patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change.	Topotecan	148-157	CD34 molecule	Homo sapiens	110-114	
11607769-5	2001	The median peak and median total yield of CD34+ cells were six-fold higher for the topotecan-filgrastim group (328/microl and 21.5 x 10(6)/kg, respectively) than for the filgrastim group (54/microl and 3.7 x 10(6)/kg, respectively).	Topotecan	83-92	CD34 molecule	Homo sapiens	42-46	
10786197-18	1999	Furthermore, topotecan demonstrated to be an effective drug to mobilize CD34+ cells for autografting.	Topotecan	13-22	CD34 molecule	Homo sapiens	72-76